press releases

 
AMMIC: New platform for Catalan companies and organizations accelerates drug R&D for minority diseases

March 2018

La Vanguardia

AMMIC: New platform for Catalan companies and organizations accelerates drug R&D for minority diseases

Acceleradora en Malalties Minoritàries de Catalunya (AMMIC) is part of the RIS3CAT community coordinated by Biocat. It is led by IUCT and other members include VHIR, Esteve, Aromics, BCN Peptides, Minoryx, Aniling and Qgenomics After its first year of work, the AMMIC project has seen its first scientific results, including the launch of a phase II/III study in Adrenoleukodystrophy, the preclinical assessment with animal models of the efficacy of three new candidate molecules to treat Malignant pleural mesothelioma, Pediatric Rhabdomyosarcoma and Myotonic dystrophy type 1. Follow the new here

 
Asbestos and cancer

December 2017

El Periodico

Asbestos and cancer

Malignant Mesothelioma is an aggresive, poor prognosis and highly refractory cancer. It is also known as the "asbestos cancer", as this mineral widely used at the industrial settings over the past century, is the main origin of the tumor. The published new established an important milestone: first sentence of a judge admiting the damage induced by asbestos to neighbours that simply lived closed to the area of influence of an asbestos' manufacture industry.  

 
Opened the crowdfunding campaign of AROMICS for a new cancer treatment

January 2017

El periódico de Catalunya

Opened the crowdfunding campaign of AROMICS for a new cancer treatment

The goal of the campaign launched by AROMICS, located at the Barcelona Science Park, is completing regulatory preclinical package of the first-in-human clinical studies of its drug NAX035 for the treatment of malignant mesothelioma, an aggressive, poor prognosis and highly treatment-resistant asbestos-associated malignancy, directly linked to asbestos exposure.

 
Aromics launches a crowdfunding campaing for its mesothelioma drug

December 2016

El periodico

Aromics launches a crowdfunding campaing for its mesothelioma drug

Aromics launches an "equity crodfunding" or collaborative financial campaign to capture 300.000 euros. The campaign is devoted to small private investors that want to participate in the project. The operation is made thru Capital Cell -a platfom accredited by Generalitat de Catalunya- specialized in Crowdfunding for biotech companies. the goal is to complete preclinical package of NAX035, a novel drug for the treatment of malignant mesothelioma, an agressive cancer realted to asbestos exposure.

 
Aromics, a development stage biopharmaceutical company

September 2015

La Vanguardia

Aromics, a development stage biopharmaceutical company

AROMICS, founded in 2005, is a development stage biopharmaceutical company working on the development of novel antitumor and antiviral agents.